February 2021 -

Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (AD) – Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model

/in presentations /by george

Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 11, 2021.

Presentation (Webinar, February 9, 2021): Capsaicin – The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target

/in presentations /by george

Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.